Antiviral Drug Strategies

Front Cover
Erik De Clercq
John Wiley & Sons, Apr 8, 2011 - Medical - 426 pages
By focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, this ready reference provides the critical knowledge needed to develop entirely novel therapeutics and to target new viruses.
It begins with a general discussion of antiviral strategies, followed by a broad survey of known viral targets, such as reverse transcriptases, proteases, neuraminidases, RNA polymerases, helicases and primases, as well as their known inhibitors. The final section contains several cases studies of recent successful antiviral drug development.
Edited by Erik de Clercq, the world authority on small molecule antiviral drugs, who has developed more new antivirals than anyone else.
 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

A Personal Foreword
InhibitionofHIVEntry
Targeting Integration Beyond Strand Transfer
From Saquinavir to Darunavir The Impact of 10 Years of Medicinal Chemistry on a Lethal Disease
Acyclicand Cyclic Nucleoside Phosphonates
HelicasePrimase Inhibitors A NewApproach
Mutations
Acknowledgments
AntiHCMV Compounds
Lethal Mutagenesis asan Unconventional
Acknowledgments
Recent Progress in the Development of
Acknowledgments
Antiviral RNAi Howto Silence Viruses
Neuraminidase Inhibitors as AntiInfluenza
Chapter

Chapter
Alkoxyalkyl Ester Prodrugs of Antiviral
Cytomegalovirus Diseases
How DoesIt Act? 15 5ClinicalProof ofConcept
Index
Copyright

Other editions - View all

Common terms and phrases

About the author (2011)

Erik De Clercq, M.D., PhD is currently President of the Rega Foundation, a member of the Belgian (Flemish) Royal Academy of Medicine and of the Academia Europaea, and a Fellow of the American Association for the Advancement of Science. He is an active Emeritus Professor of the Katholieke Universiteit Leuven (K.U.Leuven), Belgium. He is honorary doctor of the Universities of Ghent, Belgium, Athens, Greece, Ferrara, Italy, Jinan (Shandong), China, Charles (Prague), Czech Republic, and Jihoceska (Ceske Budejovice), Czech Republic, and Tours, France.
For his pioneering efforts in antiviral research, Professor De Clercq received in 1996 the Aventis award from the American Society for Microbiology, and in 2000 the Maisin Prize for Biomedical Sciences from the Belgian National Science Foundation. In 2008 he was elected Inventor of the Year by the European Union. Jointly with Dr. Anthony Fauci, Prof. De Clercq received the Dr. Paul Janssen Award for Biomedical Research in 2010.
He is the (co)inventor of a number of antiviral drugs, used for the treatment of HSV (valaciclovir, Valtrex , Zelitrex ), VZV (brivudin, Zostex , Brivirac , Zerpex ), CMV (cidofovir, Vistide ), HBV (adefovir dipivoxil, Hepsera ), and HIV infections (AIDS) (tenofovir disoproxil fumarate, Viread ).

Bibliographic information